Floatz Rating
CCC55/100
Confidence
Indicative
Sponsor
Affimed GmbH
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05883449CT.gov Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL | — | Terminated | — | — | — |
NCT02665650CT.gov Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | — | Completed | — | — | — |
NCT02321592CT.gov GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma | — | Completed | — | — | — |
NCT01221571CT.gov A Study to Assess AFM13 in Patients With Hodgkin Lymphoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hodgkins Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Anti-Cd30/Cd16A Monoclonal Antibody Afm13 (this asset) | Affimed GmbH | P2 | CCC · 55 |
| Camustine | VIVUS LLC | P2 | BBB |
| Everolimus | OHSU Knight Cancer Institute | P2 | BBB |
| Carboplatin | St. Petersburg State Pavlov Medical University | P2 | BBB |
| Cyclosporin A | City of Hope Medical Center | P3 | BBB |
| Isocyclophosphamide | St. Petersburg State Pavlov Medical University | P3 | BBB |
| Vinblastine | M.D. Anderson Cancer Center | P4 | BBB |
| Vincristine Sulfate | National Cancer Institute (NCI) | P3 | BBB |
| Irinotecan | OHSU Knight Cancer Institute | P2 | BBB |
+42 more in the Hodgkins Lymphoma cohort
Other indications for Anti-Cd30/Cd16A Monoclonal Antibody Afm13
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Mycosis Fungoides | — | P2 | BB · 69 |
| Peripheral T-Cell Lymphoma, Not Otherwise Specified | — | P2 | B · 61 |
| Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | — | P1/2 | CCC · 52 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Anti-Cd30/Cd16A Monoclonal Antibody Afm13 in Hodgkins Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/anti-cd30cd16a-monoclonal-antibody-afm13-hodgkins-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →